Point72 Hong Kong’s Revance Therapeutics, Inc. RVNC Stock Holding History

Point72 Hong Kong’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,656	Closed	-$92K	–	2500
2022 Q2	$92K	Buy	+6,656	New	+$102K	﹤0.01%	1205
2021 Q4	–	Sell	-178	Closed	-$5K	–	2492
2021 Q3	$5K	Sell	178 -6,064	-97%	-$173K	﹤0.01%	1845
2021 Q2	$185K	Buy	6,242 +5,655	+963%	+$163K	0.01%	1177
2021 Q1	$16K	Buy	+587	New	+$16.2K	﹤0.01%	1523
2020 Q4	–	Sell	-713	Closed	-$18K	–	2100
2020 Q3	$18K	Buy	+713	New	+$18.7K	﹤0.01%	896
2020 Q2	–	Sell	-234	Closed	-$3K	–	1478
2020 Q1	$3K	Sell	234 -1,717	-88%	-$35.5K	﹤0.01%	838
2019 Q4	$32K	Buy	+1,951	New	+$30.3K	0.01%	790
2019 Q3	–	Sell	-179	Closed	-$2K	–	1405
2019 Q2	$2K	Buy	+179	New	+$2.26K	﹤0.01%	1015
2018 Q2	–	Sell	-540	Closed	-$17K	–	1240
2018 Q1	$17K	Buy	+540	New	+$17.4K	0.01%	641

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Hong Kong's RVNC Position: Q3 2022 in Review

Point72 Hong Kong sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2022, closing a stake of 6,656 shares — an estimated $92K sold.

Point72 Hong Kong first reported a position in RVNC in Q1 2018 and held it in 9 quarters. The position peaked at $185K in Q2 2021. 182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

Point72 Hong Kong reported no remaining Revance Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Point72 Hong Kong sold 6,656 Revance Therapeutics, Inc. shares in Q3 2022, an estimated $92K.
Point72 Hong Kong first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
Point72 Hong Kong's Revance Therapeutics, Inc. position peaked at $185K in Q2 2021.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.